Mercator MedSystems
Mercator MedSystems develops site-specific delivery devices for the treatment of vascular, oncologic, and regenerative diseases.
- Company typePrivate
- Founded2000
- HeadquartersSan Leandro, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Mercator MedSystems does
Mercator MedSystems’ mission is to become a global leader in interventional, site-specific delivery of therapeutics that improve patient outcomes in vascular disease, oncology, and regenerative medicine. The 15th and 16th Centuries marked the beginning of the Age of Exploration, a time of bold action, vast territorial expansion and profound intellectual discovery. Gerardus Mercator (1512-1594), a mathematician and cartographer, played a key role in these ventures. He was as important to navigation as Copernicus was to astronomy. He perfected a map projection that was the first to represent the spherical surface of the earth in two dimensions. The Mercator Projection effectively transformed navigation, making it possible for ships to deliver cargo safely to any port on the globe. Inspired by the spirit of our namesake, Mercator MedSystems has developed a medical technology that enables the safe and accurate delivery of therapies anywhere in the body, ranging from drugs for diseased blood vessels, to stem cells that regenerate ailing tissues and organs. We believe this breakthrough will allow the expansion of medical therapy and stimulate profound intellectual exploration into new treatments for disease. We invite you to explore our web site, our technology and products, and to follow our progress to a new world of therapeutic delivery.
Mercator MedSystems firmographics
Firmographics- Name
- Mercator MedSystems
- Legal name
- Mercator MedSystems, Inc.
- Website
- http://mercatormed.com
- Company type
- Private
- Founded year
- 2000
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Mercator MedSystems develops site-specific delivery devices for the treatment of vascular, oncologic, and regenerative diseases.
- Ownership category
- akta.pro rank
Mercator MedSystems industry classification
Industry- Product category
- Interventional Vascular Medical Devices
- NAICS
- Surgical and Medical Instrument Manufacturing (339112), Medical Equipment and Supplies Manufacturing (3391)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Infusion Sets, Catheters & Pump Consumables (HLAHAIAH)
- akta.pro secondary industry
- Airway Management Devices (ET Tubes, LMAs, Tracheostomy, Suction) (HLAHAGAF)
Keywords
Where Mercator MedSystems is headquartered
LocationHeadquarters
- HQ city
- San Leandro
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Mercator MedSystems business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales, Others
Revenue model
- Medical Device Sales: Mercator generates revenue from the sale of its proprietary FDA-cleared and CE-marked catheter-based micro-infusion devices, including the Bullfrog Micro-Infusion Device, Leapfrog Micro-Infusion Device, and Blowfish Transbronchial Micro-Infusion Catheter. Products are sold to hospitals and interventional proceduralists for use in angiographic lab settings.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels5 records
Mercator MedSystems product offering
Product offeringCore offering
Mercator MedSystems develops and commercializes FDA-cleared and CE-marked catheter-based micro-infusion devices that enable site-specific delivery of drugs and biologics into perivascular tissues and airway walls. Its core products — the Bullfrog, Leapfrog, and Blowfish devices — use a balloon-hydraulically-deployed micro-needle to deposit therapeutics around diseased vessels or airways, avoiding the off-target effects of systemic delivery.
Product overview
Mercator MedSystems offers a platform of catheter-based micro-infusion technologies for localized drug delivery. The core products include the Bullfrog Micro-Infusion Device and Leapfrog Micro-Infusion Device (for peripheral vasculature), and the Blowfish Transbronchial Micro-Infusion Catheter (for airways). These FDA-cleared and CE-marked devices use a balloon that hydraulically deploys a micro-needle through vessel walls to deposit therapeutics into perivascular tissues, enabling targeted delivery of pharmacologics and biologics instead of systemic administration.
Differentiator
Problem solved
Functional benefit
Products and services
- Bullfrog Micro-Infusion Device FDA-cleared and CE-marked catheter-based device that uses a balloon-hydraulically-deployed micro-needle to deliver drugs and biologics into perivascular tissues around arteries or veins (2-16 mm diameter). Used by interventional cardiologists, vascular surgeons, and interventional radiologists in angiographic lab settings.
- Leapfrog Micro-Infusion Device FDA-cleared and CE-marked catheter-based micro-infusion device similar to the Bullfrog, with a balloon that hydraulically deploys a micro-needle through the vessel wall for perivascular drug delivery.
- Blowfish Transbronchial Micro-Infusion Catheter FDA-cleared and CE-marked catheter for the delivery of drugs and biologics into airways, enabling precision drug delivery to airway walls for treatment of bronchial conditions including malignant airway obstruction, asthma, and chronic bronchitis.
Quantifiable outcome
- 51.3% relative reduction in clinically relevant target lesion failure (6-month) with temsirolimus local delivery in TANGO Phase 2 trial versus sham control
- +6 more outcomes
Companies that use Mercator MedSystems
Customer profileNamed customers4 records
Segments2 records
Ideal customer profiles2 records
Mercator MedSystems technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Mercator MedSystems partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered minor and core.
- Vascular Breakthroughs, LLCminorVascular Breakthroughs, LLC announced first New England enrollment into the DEXTERITY clinical trials, partnering with Vascular Care Connecticut to expand Mercator's clinical trial site network for local anti-inflammatory DVT therapy studies.
- Vascular Care ConnecticutminorVascular Care Connecticut partnered with Vascular Breakthroughs, LLC to serve as a clinical trial enrollment site for Mercator's DEXTERITY clinical trials, marking first New England enrollment in the DVT local anti-inflammatory therapy studies.
- Massachusetts General Hospital (MGH), Harvard Medical SchoolcoreMGH research team led by Dr. Farouc Jaffer serves as co-principal investigator for the NIH STTR grant research. The collaboration focuses on preclinical models to demonstrate mechanisms of DVT and restoration of blood flow, measuring molecular, physiologic, and biologic outcomes of anti-inflammatory drug delivery locally around veins. The partnership leverages MGH's extensive experience in preclinical DVT modeling.
- Sentara Healthcare / Sentara Norfolk General HospitalcoreDr. David Dexter of Sentara Vascular Specialists enrolled the first patient in the DEXTERITY-AFP clinical trial on October 29, 2021, at Sentara Norfolk General Hospital in Virginia. Dr. Dexter serves as Principal Investigator and worldwide co-Principal Investigator for the DEXTERITY-AFP trial, playing a central role in Mercator's key clinical development program for DVT treatment.
Scale indicators3 records
Recent moves6 records
Expansion highlights5 records
Mercator MedSystems competitors and assessment
Company assessmentDirect peers
- Penumbra: Penumbra's Indigo System is a leading catheter-based thrombectomy device for DVT treatment, directly competing with Mercator's DEXTERITY program in the same physician call point (interventional radiologists/vascular surgeons) and addressing the same post-thrombotic syndrome population.
- AngioDynamics: AngioDynamics manufactures vascular interventional devices including mechanical thrombectomy (AlphaVac, AngioJet) and ablation catheters, serving the same endovascular specialists who would adopt Mercator's micro-infusion devices for DVT and below-knee PAD.
Emerging players
- SurModics: SurModics develops drug-delivery coating technologies for vascular devices, addressing the same clinical need (restenosis prevention) through surface drug elution rather than Mercator's perivascular micro-infusion, making it the most direct technology analogue in the local-delivery space.
- RenovaCare: RenovaCare develops cell spray and local delivery technologies for regenerative medicine and wound care, sharing Mercator's platform-based approach to localized therapeutic delivery outside of systemic administration.
Peers
- BioCardia:
Broad incumbents
- Cardiovascular Systems (Abbott): CSI (acquired by Abbott) developed Diamondback atherectomy for peripheral arterial disease including below-knee lesions, directly competing for the same procedural slot in below-knee revascularization where Mercator's TANGO trial temsirolimus delivery is positioned.
- Shockwave Medical (Johnson & Johnson): Shockwave's intravascular lithotripsy (IVL) for calcified peripheral and coronary artery disease targets the same vascular interventional call points and increasingly competes with drug-based approaches for below-knee PAD treatment.
- Medtronic: Medtronic is a dominant interventional cardiology and peripheral vascular device manufacturer with drug-coated balloons (IN.PACT) and renal denervation programs that compete with Mercator's perivascular micro-infusion across DVT, PAD, and hypertension indications.
- Boston Scientific: Boston Scientific's peripheral interventional portfolio (Eluvia drug-eluting stent, Ranger DCB) and interventional oncology/catheter platforms overlap with Mercator's addressable indications and physician customer base.
- Abbott Vascular: Abbott's vascular division (XIENCE, Esprit, StarClose) competes in peripheral and coronary vascular intervention with both drug-eluting and mechanical solutions that target overlapping patient populations with Mercator's micro-infusion devices.
Market position
Strengths1 record
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Mercator MedSystems social profiles
Digital presenceMercator MedSystems compliance and trust
Trust signalCompliance2 records
Mercator MedSystems financial estimates
Financial estimateRevenue estimate
Valuation estimate
Mercator MedSystems leadership team
Management profileNumber of profiles
Profiles8 records
Mercator MedSystems funding detail
Funding detailFunding overview
Funding rounds4 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Mercator MedSystems M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Mercator MedSystems
What does Mercator MedSystems do?
Mercator MedSystems develops and commercializes FDA-cleared and CE-marked catheter-based micro-infusion devices that enable site-specific delivery of drugs and biologics into perivascular tissues and airway walls. Its core products — the Bullfrog, Leapfrog, and Blowfish devices — use a balloon-hydraulically-deployed micro-needle to deposit therapeutics around diseased vessels or airways, avoiding the off-target effects of systemic delivery.
Is Mercator MedSystems a public or private company?
Mercator MedSystems is a private company. It is classified as venture growth investor backed and is currently operating.
When was Mercator MedSystems founded?
Mercator MedSystems was founded in 2000. It employs 11 to 50 people.
Where is Mercator MedSystems based?
Mercator MedSystems is headquartered in San Leandro, United States, in the North America region.
How does Mercator MedSystems make money?
One revenue line is on record: medical Device Sales.
Who are Mercator MedSystems's main competitors?
Direct peers on record are Penumbra and AngioDynamics. Emerging players are SurModics and RenovaCare. BioCardia is listed as a peer. Broad incumbents are Cardiovascular Systems (Abbott), Shockwave Medical (Johnson & Johnson), Medtronic, Boston Scientific and Abbott Vascular.
Does Mercator MedSystems have an API?
No public API is recorded for Mercator MedSystems.
What industry is Mercator MedSystems in?
Mercator MedSystems's product category is Interventional Vascular Medical Devices. Its primary akta.pro industry code is HLAHAIAH, Infusion Sets, Catheters & Pump Consumables, with a secondary code of HLAHAGAF, Airway Management Devices (ET Tubes, LMAs, Tracheostomy, Suction). Its NAICS code is 339112 and its SIC code is 3841.